Understanding the difference between response and remission changes how treatment success is measured. Justin Ray, MSN, PMHNP-BC of South Chesapeake Psychiatry lays the foundations and explains what the research means for medication management and depression treatment in Chesapeake, VA.
As I begin this weekly newsletter, it feels important to start with the foundations, not in the sense of oversimplifying complex science, but in the sense of clarifying the language we use to describe it.
Medical research, and psychopharmacology research in particular, relies on a shared vocabulary. These terms appear in journal articles, conference presentations, FDA briefing documents, and pharmaceutical slide decks. They sound intuitive. They sound reassuring. And yet, they often mean something far more specific and far more limited than we assume when we hear them used clinically.
If we do not understand the language of research, we risk misunderstanding the results.
Over the years, speaking for the psychopharmacology industry and presenting at conferences on disease states and treatments, I have found myself repeatedly using a handful of words that deserve closer examination: response, remission, recovery, and the outcomes that follow or undo them.
Let us start at the beginning.
In medical research, response refers to a predefined, measurable improvement from baseline. It does not mean that someone is well. It does not mean symptoms are gone. It means that a participant met a criterion that was specified before the study ever began.
In antidepressant trials, for example, response is commonly defined as a 50 percent or greater reduction from baseline on a rating scale such as the MADRS. A participant who enters a study with a MADRS score of 32 and improves to 16 is labeled a responder, even if they remain symptomatic, functionally impaired, or distressed. From a research perspective, the endpoint has been met.
Remission represents a higher bar, but it is still a symptom based construct. Remission usually means that scores have fallen below a predetermined cutoff, often a MADRS score in the range of 10 to 12 or lower. This indicates that symptoms are quieter according to the instrument being used. It does not tell us whether cognition has recovered, motivation has returned, or day to day functioning has normalized.
Because symptoms fluctuate, research often adds a time component in the form of sustained remission. This term indicates that remission has been maintained over a defined period, reducing the likelihood that an outcome reflects a brief or unstable improvement. It is a stronger signal, but still one focused primarily on symptoms.
Beyond remission lies territory that research measures far less consistently.
Recovery generally implies a return to premorbid or normative levels of functioning. It extends beyond symptom counts to include stability, independence, and real world engagement. Because recovery is harder to define and measure, it is rarely used as a primary endpoint in trials.
Closely related is functional recovery, which emphasizes practical outcomes such as the ability to work, maintain relationships, manage daily responsibilities, and participate meaningfully in life, even if some symptoms persist. From a clinical standpoint, this is often what matters most. From a research standpoint, it is complex, variable, and difficult to standardize.
Just as important as improvement is understanding loss of improvement.
Relapse refers to the return of symptoms after response or remission, often defined by crossing a symptom threshold again. Recurrence typically describes the onset of a new episode after a longer period of recovery. These distinctions matter in long term studies, where durability rather than initial improvement is the true test of effectiveness.
All of these outcomes sit on top of another critical layer of research design: endpoints.
A primary endpoint is the main outcome a study is designed and powered to assess. It is the question the trial is formally asking. Secondary endpoints examine additional outcomes of interest, but the study is not primarily built around them. Positive secondary findings can be informative, but they are more vulnerable to chance and should be interpreted accordingly.
Then there is post hoc, or exploratory, data.
These analyses are conducted after the study is complete, often to explore patterns the trial was not originally designed to test. Post hoc findings can be incredibly valuable. They frequently generate new hypotheses, reveal subgroup effects, or highlight domains like cognition or function that were underappreciated at the outset. But they are not definitive. They are signals, not conclusions.
Understanding the difference matters. A statistically significant primary endpoint carries a different weight than an exploratory observation, even when both are clinically interesting.
This is where much of the disconnect between research and practice emerges. A study may be technically positive while offering modest functional benefit. Another may miss its primary endpoint yet reveal compelling post hoc data that reshapes how clinicians think about a treatment’s real world role.
None of this means research is misleading. It means research is precise, and precision requires context.
Response tells us that change occurred, remission tells us that symptoms are controlled, sustained remission tells us that the change lasted and recovery and functional recovery ask whether a life was actually restored.
Understanding where a study’s findings sit along this continuum is essential if we want to translate evidence into meaningful care.
This newsletter exists in that interpretive space between the rigor of study design and the reality of the clinic. Before we debate what is new, innovative, or disruptive, we need to agree on what our outcome language actually means.
Otherwise, we risk confusing statistical success with clinical success and mistaking movement on a scale for progress in a person’s life.
That is the foundation. Everything that follows builds on it.
Response usually means a meaningful reduction in symptoms, while remission means symptoms have largely resolved and function is restored. Both are important goals in psychiatric treatment.
South Chesapeake Psychiatry offers psychiatric evaluation and medication management in Chesapeake, VA, with in-person and telepsychiatry visits across Hampton Roads.
Yes. South Chesapeake Psychiatry provides virtual psychiatric care in VA and telehealth medication management for patients across Hampton Roads.
South Chesapeake Psychiatry provides expert psychiatric care and medication management in Chesapeake, VA, with in-person visits and secure telepsychiatry for patients across Hampton Roads and throughout Virginia. To request an appointment for psychiatric evaluation and medication management, contact South Chesapeake Psychiatry today.
To schedule an appointment with South Chesapeake Psychiatry, call 757-908-2124.
This article is for educational purposes only and is not medical advice. Always consult a qualified clinician about your individual care.
Schedule an appointment today to get diagnosed, receive a prescription, and continue your journey towards mental peace.
